Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder

Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced a...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatric disease and treatment 2006-12, Vol.2 (4), p.467-473
Main Authors: Liu, Feng, Minami, Haruka, Silva, Raul R
Format: Article
Language:English
Subjects:
Attention deficit hyperactivity disorder
Drug therapy
Expert Opinion
Pharmacodynamics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of medications. This paper reviews and summarizes the available research literature on d-MPH regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, and clinical perspectives. d-MPH potentially may offer some advantages in the realms of absorption and duration of action compared with its racemic counterpart. The differences in pharmacokinetics and clinical implications of the immediate-release and extended-release forms of d-MPH are also compared and contrasted.
ISSN:1176-6328
1178-2021
DOI:10.2147/nedt.2006.2.4.467